Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Concert Pharmaceuticals stock

CNCE
US2060221056
A1XEAC

Price

8.37
Today +/-
+0
Today %
+0 %
P

Concert Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Concert Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Concert Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Concert Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Concert Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Concert Pharmaceuticals Stock Price History

DateConcert Pharmaceuticals Price
3/6/20238.37 undefined
3/3/20238.37 undefined

Concert Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Concert Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Concert Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Concert Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Concert Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Concert Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Concert Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Concert Pharmaceuticals’s growth potential.

Concert Pharmaceuticals Revenue, EBIT and net profit per share

DateConcert Pharmaceuticals RevenueConcert Pharmaceuticals EBITConcert Pharmaceuticals Net Income
2028e393.58 M undefined0 undefined80.58 M undefined
2027e280.94 M undefined78.9 M undefined34.04 M undefined
2026e195.14 M undefined3.77 M undefined1.22 M undefined
2025e98.28 M undefined-79.06 M undefined-40.17 M undefined
2024e32.38 M undefined-129.49 M undefined-101.39 M undefined
2023e13.12 M undefined-137.33 M undefined-134.31 M undefined
2022e101,745 undefined-123.74 M undefined-135.59 M undefined
202132.58 M undefined-77.51 M undefined-80.05 M undefined
20207.9 M undefined-72.6 M undefined-74.8 M undefined
20191.1 M undefined-79 M undefined-78.2 M undefined
201810.5 M undefined-55.6 M undefined-56 M undefined
2017143.9 M undefined92.6 M undefined95.2 M undefined
2016200,000 undefined-51.2 M undefined-50.7 M undefined
201566.7 M undefined24.8 M undefined24.2 M undefined
20148.6 M undefined-30.6 M undefined-31.8 M undefined
201325.4 M undefined-4.4 M undefined-6.5 M undefined
201212.8 M undefined-18.6 M undefined-20.8 M undefined
201119.5 M undefined-11.3 M undefined-12.4 M undefined

Concert Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201120122013201420152016201720182019202020212022e2023e2024e2025e2026e2027e2028e
19122586601431017320133298195280393
--36.84108.33-68.00725.00---93.01-90.00600.00357.14--146.15206.2598.9843.5940.36
------------------
000000000000000000
-11-18-4-3024-5192-55-79-72-77-123-137-129-793780
-57.89-150.00-16.00-375.0036.36-64.34-550.00-7,900.00-1,028.57-240.63--1,053.85-403.13-80.611.5427.86-
-12-20-6-3124-5095-56-78-74-80-135-134-101-4013480
-66.67-70.00416.67-177.42-308.33-290.00-158.9539.29-5.138.1168.75-0.74-24.63-60.40-102.503,300.00135.29
11.211.211.215.822.322.223.423.423.731.234.410000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Concert Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Concert Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021
                     
42.727.632.779.2142.296.2203.2160.8111.8131.9143.1
0.500.210.100.2160.10.70.22
0.10.10.10.30.20.20.60.60.22.50
00000000000
0.91.21.11.21.71.41.82.74.77.67.01
44.228.934.181.7144.297.8205.8180.1116.8142.7150.33
4.43.52.52.32.32.22.28.91715.313.83
00000000000
0000002.22.32.400
00000000000
00000000000
0.80.83.30.50.50.51.61.21.31.21.16
5.24.35.82.82.82.7612.420.716.514.99
49.433.239.984.5147100.5211.8192.5137.5159.2165.32
                     
111.5111.8112.200000000.03
0.40.91.5200.2251.8257.5273.1284.4296.1400.6461.77
-87.1-107.6-113.6-145.3-121.2-171.9-76.2-116.5-194.7-269.4-349.5
000000000-0.1-0.08
000000-0.4-0.1000
24.85.10.154.9130.685.6196.5167.8101.4131.1112.23
1.60.810.60.50.50.71.30.90.22.61
0.40.40.92.53.22.53.43.74.45.35.87
7.91.65.98.42.92.52.43.7124.67.65
00000000000
0.35.18.27.10000000
10.27.91618.66.65.56.58.717.310.116.12
815.57.400000000
00000000000
6.34.616.4119.79.28.916.118.717.936.97
14.320.123.8119.79.28.916.118.717.936.97
24.52839.829.616.314.715.424.8362853.09
49.333.139.984.5146.9100.3211.9192.6137.4159.1165.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Concert Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Concert Pharmaceuticals's financial health and stability.

Assets

Concert Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Concert Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Concert Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Concert Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20112012201320142015201620172018201920202021
-11-20-6-3124-5095-56-78-74-80
1,0001,0001,0001,000001,0001,0001,0001,0001,000
00000000000
-9-816-1-50-2416-107
11023592111415
01,0001,0001,0000000000
0000001,0000000
-18-2613-2923-45104-48-48-69-55
0000000-2000
22-1-3-4414-7-1213782052
230-3-4315-6-1204083052
00000000000
712-5-8-70-10000
000864806017064
712-7784105019267
00-2000000222
00000000000
11-152379-51-11-10352464
-18.4-26.912.6-30.622.2-46.1103.2-50.9-49.5-69.2-55.41
00000000000

Concert Pharmaceuticals stock margins

The Concert Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Concert Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Concert Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Concert Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Concert Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Concert Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Concert Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Concert Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Concert Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Concert Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Concert Pharmaceuticals Margin History

Concert Pharmaceuticals Gross marginConcert Pharmaceuticals Profit marginConcert Pharmaceuticals EBIT marginConcert Pharmaceuticals Profit margin
2028e0 %0 %20.47 %
2027e0 %28.08 %12.12 %
2026e0 %1.93 %0.63 %
2025e0 %-80.44 %-40.87 %
2024e0 %-399.92 %-313.15 %
2023e0 %-1,046.99 %-1,023.95 %
2022e0 %-121,614.29 %-133,259.7 %
20210 %-237.92 %-245.72 %
20200 %-918.99 %-946.84 %
20190 %-7,181.82 %-7,109.09 %
20180 %-529.52 %-533.33 %
20170 %64.35 %66.16 %
20160 %-25,600 %-25,350 %
20150 %37.18 %36.28 %
20140 %-355.81 %-369.77 %
20130 %-17.32 %-25.59 %
20120 %-145.31 %-162.5 %
20110 %-57.95 %-63.59 %

Concert Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Concert Pharmaceuticals earnings per share therefore indicates how much revenue Concert Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Concert Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Concert Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Concert Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Concert Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Concert Pharmaceuticals Revenue, EBIT and net profit per share

DateConcert Pharmaceuticals Sales per ShareConcert Pharmaceuticals EBIT per shareConcert Pharmaceuticals Earnings per Share
2028e8.2 undefined0 undefined1.68 undefined
2027e5.85 undefined0 undefined0.71 undefined
2026e4.06 undefined0 undefined0.03 undefined
2025e2.05 undefined0 undefined-0.84 undefined
2024e0.67 undefined0 undefined-2.11 undefined
2023e0.27 undefined0 undefined-2.8 undefined
2022e0 undefined0 undefined-2.82 undefined
20210.95 undefined-2.25 undefined-2.33 undefined
20200.25 undefined-2.33 undefined-2.4 undefined
20190.05 undefined-3.33 undefined-3.3 undefined
20180.45 undefined-2.38 undefined-2.39 undefined
20176.15 undefined3.96 undefined4.07 undefined
20160.01 undefined-2.31 undefined-2.28 undefined
20152.99 undefined1.11 undefined1.09 undefined
20140.54 undefined-1.94 undefined-2.01 undefined
20132.27 undefined-0.39 undefined-0.58 undefined
20121.14 undefined-1.66 undefined-1.86 undefined
20111.74 undefined-1.01 undefined-1.11 undefined

Concert Pharmaceuticals business model

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Concert Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Concert Pharmaceuticals Revenue by Segment

Segmente2021202020192018
Other revenue32.54 M USD---
License and Research and Development Revenue---10.51 M USD
License and research and development revenue39,000 USD7.9 M USD1.08 M USD-
Product and Service, Other----

Concert Pharmaceuticals SWOT Analysis

Strengths

Concert Pharmaceuticals Inc has several strengths that contribute to its success in the industry. Firstly, the company has a strong research and development (R&D) team consisting of experienced scientists and researchers. This allows them to continuously innovate and develop new drugs and therapies.

Secondly, Concert Pharmaceuticals has a diverse product portfolio, catering to various therapeutic areas. This diversification helps mitigate risks associated with dependence on a single product or therapeutic category.

Furthermore, the company has established strategic partnerships with leading pharmaceutical companies, enabling them to leverage their resources and expertise. These alliances provide Concert Pharmaceuticals with access to wider distribution channels and increased market presence.

Weaknesses

Despite its strengths, Concert Pharmaceuticals Inc also faces certain weaknesses. One weakness is its relatively small size compared to some of its larger competitors. This limits their financial resources and may restrict their ability to invest in extensive marketing campaigns or infrastructure.

Additionally, Concert Pharmaceuticals heavily relies on its R&D efforts for revenue generation. Any delays or failures in the development of new drugs can negatively impact their financial performance.

Moreover, the company operates in a highly regulated industry, which poses challenges in terms of compliance with various regulations and obtaining necessary approvals for product launch.

Opportunities

Concert Pharmaceuticals Inc has several opportunities to capitalize on. One significant opportunity is the increasing demand for innovative therapies and personalized medicine. Concert Pharmaceuticals can leverage its R&D capabilities to develop breakthrough treatments that cater to these evolving healthcare needs.

Furthermore, the aging population and the rising prevalence of chronic diseases provide an expanding market for pharmaceutical companies. Concert Pharmaceuticals can target these demographics by developing drugs and therapies specifically tailored to their needs.

Additionally, the growing focus on emerging markets presents an opportunity for Concert Pharmaceuticals to expand its geographical presence and tap into new customer bases.

Threats

Concert Pharmaceuticals Inc faces certain threats that could impact its business. One major threat is the intense competition within the pharmaceutical industry. Large established companies have significant resources and established brand names, making it challenging for smaller players like Concert Pharmaceuticals to compete.

Another threat is the potential for regulatory changes or stricter regulations. Any changes in regulations could impact the company's ability to develop or market its products.

Moreover, the emergence of generic drug manufacturers poses a threat to Concert Pharmaceuticals. Generic drugs can enter the market at lower prices, potentially reducing demand for the company's branded products.

Concert Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Concert Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Concert Pharmaceuticals shares outstanding

The number of shares was Concert Pharmaceuticals in 2023 — This indicates how many shares 34.405 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Concert Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Concert Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Concert Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Concert Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Concert Pharmaceuticals.

Concert Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-0.6 -0.58  (3.94 %)2022 Q3
6/30/2022-0.86 -0.59  (31.75 %)2022 Q2
3/31/2022-0.93 -1.03  (-10.48 %)2022 Q1
12/31/2021-0.74 -1.01  (-35.64 %)2021 Q4
9/30/2021-0.83 -0.78  (5.59 %)2021 Q3
6/30/2021-0.75 0.16  (121.31 %)2021 Q2
3/31/2021-0.7 -0.67  (4.53 %)2021 Q1
12/31/2020-0.79 -0.69  (12.82 %)2020 Q4
9/30/2020-0.75 -0.6  (19.97 %)2020 Q3
6/30/2020-0.7 -0.41  (41.74 %)2020 Q2
1
2
3
4

Concert Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.20473 % Kynam Capital Management LP4,420,3492,747,30812/31/2022
7.55686 % BVF Partners L.P.3,629,000012/31/2022
3.97934 % The Vanguard Group, Inc.1,910,98469,21412/31/2022
3.60744 % Nantahala Capital Management, LLC1,732,388-54,77112/31/2022
3.00220 % Millennium Management LLC1,441,735122,22712/31/2022
2.89718 % Citadel Advisors LLC1,391,302269,87312/31/2022
2.79098 % Point72 Asset Management, L.P.1,340,3001,069,70012/31/2022
2.72452 % BofA Global Research (US)1,308,3864,39112/31/2022
2.69838 % Ingalls & Snyder LLC (Asset Management)1,295,833-34,60012/31/2022
2.50608 % Parkman Healthcare Partners LLC1,203,48465,89712/31/2022
1
2
3
4
5
...
10

Concert Pharmaceuticals Executives and Management Board

Dr. Roger Tung62
Concert Pharmaceuticals President, Chief Executive Officer, Co-Founder, Director (since 2006)
Compensation 3.53 M
Ms. Nancy Stuart64
Concert Pharmaceuticals Chief Operating Officer
Compensation 1.58 M
Dr. James Cassella67
Concert Pharmaceuticals Chief Development Officer
Compensation 1.51 M
Mr. Marc Becker50
Concert Pharmaceuticals Chief Financial Officer
Compensation 1.38 M
Mr. Richard Aldrich67
Concert Pharmaceuticals Independent Chairman of the Board, Co-founder
Compensation 129,054
1
2
3

Concert Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Processa Pharmaceuticals Stock
Processa Pharmaceuticals
SupplierCustomer0,75-0,10-0,40-0,240,15-
Otsuka Holdings Stock
Otsuka Holdings
SupplierCustomer0,670,440,570,480,220,10
Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals
SupplierCustomer0,430,240,190,17-0,090,42
1

Most common questions regarding Concert Pharmaceuticals

What values and corporate philosophy does Concert Pharmaceuticals represent?

Concert Pharmaceuticals Inc is a leading biopharmaceutical company committed to developing innovative therapies for various diseases. The company's core values revolve around scientific excellence, perseverance, and dedication to patient well-being. With a mission to address unmet medical needs, Concert focuses on discovering and developing small molecule drugs through its proprietary deuterium chemistry platform. By leveraging its expertise, Concert Pharmaceuticals strives to create value for patients, healthcare providers, and shareholders alike. The company's corporate philosophy emphasizes integrity, collaboration, and a patient-centric approach, which are the driving forces behind its continuous pursuit of groundbreaking therapeutic solutions.

In which countries and regions is Concert Pharmaceuticals primarily present?

Concert Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Concert Pharmaceuticals achieved?

Concert Pharmaceuticals Inc has achieved several significant milestones. The company successfully advanced its pipeline product, CTP-543, into late-stage development for alopecia areata. Moreover, Concert Pharmaceuticals Inc received FDA Fast Track designation for CTP-543, reinforcing its potential as a promising treatment option. The company also entered into a licensing agreement with Vertex Pharmaceuticals for CTP-656, a next-generation treatment for cystic fibrosis. Furthermore, Concert Pharmaceuticals Inc successfully completed a Phase 1 trial for CTP-692, a potential treatment for schizophrenia. These accomplishments highlight the company's dedication to developing innovative therapies and solidify its position in the pharmaceutical industry.

What is the history and background of the company Concert Pharmaceuticals?

Concert Pharmaceuticals Inc is a renowned pharmaceutical company with an impressive history and background. Founded in 2006, the company focuses on developing innovative therapies for various medical conditions. Concert Pharmaceuticals Inc has been dedicated to utilizing deuterium chemistry to create novel drugs with improved pharmacokinetic properties. Through strategic collaborations and research, it has successfully advanced its pipeline, including potential treatments for inflammation and central nervous system disorders. With a strong commitment to scientific excellence and a talented team, Concert Pharmaceuticals Inc continues to make significant contributions to the healthcare industry by addressing unmet medical needs and improving patients' lives.

Who are the main competitors of Concert Pharmaceuticals in the market?

The main competitors of Concert Pharmaceuticals Inc in the market include Biocryst Pharmaceuticals, Kadmon Holdings, Inc., and Ironwood Pharmaceuticals.

In which industries is Concert Pharmaceuticals primarily active?

Concert Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of Concert Pharmaceuticals?

The business model of Concert Pharmaceuticals Inc is focused on the discovery and development of novel small molecule drugs. The company leverages its DCE Platform® (deuterated chemical entity) to create potential new medicines with improved therapeutic properties. With a strong emphasis on targeted therapies, Concert Pharmaceuticals aims to address unmet medical needs across various therapeutic areas. By utilizing its proprietary technology and partnering with pharmaceutical companies, Concert Pharmaceuticals strives to deliver innovative and differentiated treatments to patients.

What is the P/E ratio of Concert Pharmaceuticals 2024?

The Concert Pharmaceuticals P/E ratio is -2.84.

What is the P/S ratio of Concert Pharmaceuticals 2024?

The Concert Pharmaceuticals P/S ratio is 8.89.

What is the AlleAktien quality score of Concert Pharmaceuticals?

The AlleAktien quality score for Concert Pharmaceuticals is 5/10.

What is the revenue of Concert Pharmaceuticals 2024?

The expected Concert Pharmaceuticals revenue is 32.38 M USD.

How high is the profit of Concert Pharmaceuticals 2024?

The expected Concert Pharmaceuticals profit is -101.39 M USD.

What is the business model of Concert Pharmaceuticals

Concert Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel drugs for serious diseases. The company's business model is based on the discovery and development of small molecules that modulate the activity of enzymes or receptors to treat underlying pathologies. The company operates in various areas, including oncology, CNS disorders, and inflammatory diseases. In oncology, Concert Pharmaceuticals Inc is developing an innovative antibody-drug conjugate that targets a specific cancer target structure. The goal is to design a targeted cancer therapy that is less toxic to normal cells and has fewer side effects. In the CNS area, the company is working on a drug to treat depressive disorders that increases the activity levels of neurotransmitters such as serotonin and norepinephrine. The company is also developing a drug for schizophrenia, which works by increasing the activity of the glutamate receptor to reduce the symptoms of the disease. Lastly, Concert Pharmaceuticals Inc is developing new therapies for inflammatory diseases by focusing on a specific group of enzymes responsible for the inflammatory process. The company is currently researching a class of drugs that target these enzymes and provide effective anti-inflammatory effects. Additionally, the company also has a portfolio of products already on the market. These include CTP-656, a drug for cystic fibrosis, and CTP-543, a drug for alopecia areata. Both drugs are in Phase 3 of clinical development. Concert Pharmaceuticals Inc's business model relies on collaboration with other companies in the industry. Partners include global pharmaceutical companies that integrate the company's products into their own commercial infrastructures. In addition to partnerships, the company also builds strategic alliances with leading academic research institutions and biotechnology companies to expand its discovery and development activities. The company is funded through public funding and private investors. A significant source of revenue is also the licensing income from the commercialization of developed drugs. After the products are launched in the market, the company generates additional revenue through their sales. Overall, Concert Pharmaceuticals Inc's business model offers significant advantages due to its innovative research and partnerships. By developing products in various areas, the company has numerous opportunities to increase its revenues and continually advance the industry with new innovative therapies.

What is the Concert Pharmaceuticals dividend?

Concert Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Concert Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Concert Pharmaceuticals or the company does not pay out a dividend.

What is the Concert Pharmaceuticals ISIN?

The ISIN of Concert Pharmaceuticals is US2060221056.

What is the Concert Pharmaceuticals WKN?

The WKN of Concert Pharmaceuticals is A1XEAC.

What is the Concert Pharmaceuticals ticker?

The ticker of Concert Pharmaceuticals is CNCE.

How much dividend does Concert Pharmaceuticals pay?

Over the past 12 months, Concert Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Concert Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Concert Pharmaceuticals?

The current dividend yield of Concert Pharmaceuticals is .

When does Concert Pharmaceuticals pay dividends?

Concert Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Concert Pharmaceuticals?

Concert Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Concert Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Concert Pharmaceuticals located?

Concert Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Concert Pharmaceuticals from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Concert Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Concert Pharmaceuticals in the year 2023?

In the year 2023, Concert Pharmaceuticals distributed 0 USD as dividends.

In which currency does Concert Pharmaceuticals pay out the dividend?

The dividends of Concert Pharmaceuticals are distributed in USD.

All fundamentals about Concert Pharmaceuticals

Our stock analysis for Concert Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Concert Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.